Proof-of-Concept in Developing a 45% Drug Loaded Amorphous Nanoparticle Formulation

Delivering poorly soluble drugs remains a challenge in pharmaceutical science. Amorphous solid dispersions have shown promise in improving drug solubility and bioavailability. However, conventional methods often restrict drug loadings to below 20%, which can be insufficient for high-dose therapies. This limitation can lead to increased pill burden and reduced patient compliance. While amorphous nanoparticles can maintain supersaturation during absorption, their production and stabilization remain technically complex. Prior research has demonstrated that amorphous dispersions can release drug-rich nanoparticles upon dissolution. Yet, no prior work had resolved how to achieve high drug loadings while maintaining re-dispersibility. This gap motivated researchers to explore alternative formulation approaches. The need for a high drug loading formulation that can dissolve and release nanoparticles efficiently is evident. Existing methods have not fully addressed this need. This study aimed to develop a formulation that could overcome these limitations.

The study aimed to create a high drug loading amorphous nanoparticle formulation suitable for oral delivery. The objective was to engineer a formulation that could spontaneously release drug-rich nanoparticles upon contact with an aqueous environment. This approach could help reduce pill burden for high-dose therapies. The researchers focused on overcoming the limitations of conventional amorphous solid dispersions. They sought to develop a re-dispersible dosage form that maintains nanoparticle stability. The study also aimed to evaluate the impact of various process variables on formulation performance. The ultimate goal was to produce a formulation that could match or exceed the bioavailability of existing tablet forms. This work could provide a proof-of-concept for advanced drug delivery systems.

The researchers used solvent/anti-solvent precipitation to engineer nanoparticles directly. The resulting nanoparticle suspension was then concentrated and solidified into a re-dispersible dosage form. Spray drying and lyophilization were employed to achieve this. Dynamic light scattering was used to assess nanoparticle size and distribution. Scanning electron microscopy provided insights into the morphology of the solid dosage forms. High performance liquid chromatography measured drug content and release profiles. Nuclear magnetic resonance and differential scanning calorimetry evaluated the amorphous nature of the formulations. These methods allowed the team to assess the impact of process variables on final product characteristics.

Spray drying resulted in a non-re-dispersible formulation, which limited its practical application. In contrast, lyophilization with sucrose or trehalose produced re-dispersible lyocakes. Trehalose-containing lyocakes demonstrated comparable performance to a reference tablet in the fasted state. However, these formulations showed a lower area under the curve in the fed state. Dynamic light scattering confirmed nanoparticle size stability during processing. Scanning electron microscopy revealed distinct morphological differences between spray-dried and lyophilized forms. Nuclear magnetic resonance and differential scanning calorimetry confirmed the amorphous nature of the drug in the lyocakes. These findings suggest that lyophilization with trehalose is a viable method for high drug loading formulations.

The study demonstrates a proof-of-concept for high drug loading amorphous nanoparticle formulations. Lyophilization with trehalose produced a re-dispersible dosage form suitable for oral delivery. The researchers observed that spray drying was not effective for this purpose. Trehalose-containing lyocakes showed comparable performance to a reference tablet in the fasted state. However, lower bioavailability was observed in the fed state. These findings suggest that formulation choice significantly impacts in vivo performance. The authors propose that lyophilization with trehalose is a promising approach for high drug loading systems. Further work may explore ways to improve fed-state performance.